|
1
|
Yanovski SZ and Yanovski JA: Long-term
drug treatment for obesity: A systematic and clinical review. JAMA.
311:74–86. 2014. View Article : Google Scholar :
|
|
2
|
Flavin R, Peluso S, Nguyen PL and Loda M:
Fatty acid synthase as a potential therapeutic target in cancer.
Future Oncol. 6:551–562. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Santolla MF, Lappano R, De Marco P, Pupo
M, Vivacqua A, Sisci D, Abonante S, Iacopetta D, Cappello AR, Dolce
V, et al: G protein-coupled estrogen receptor mediates the
up-regulation of fatty acid synthase induced by 17β-estradiol in
cancer cells and cancer-associated fibroblasts. J Biol Chem.
287:43234–43245. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chuang HY, Chang YF and Hwang JJ:
Antitumor effect of orlistat, a fatty acid synthase inhibitor, is
via activation of caspase-3 on human colorectal carcinoma-bearing
animal. Biomed Pharmacother. 65:286–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rossato FA, Zecchin KG, La Guardia PG,
Ortega RM, Alberici LC, Costa RA, Catharino RR, Graner E, Castilho
RF and Vercesi AE: Fatty acid synthase inhibitors induce apoptosis
in non-tumorigenic melana cells associated with inhibition of
mitochondrial respiration. PLoS One. 9:e1010602014. View Article : Google Scholar
|
|
6
|
Little JL, Wheeler FB, Fels DR, Koumenis C
and Kridel SJ: Inhibition of fatty acid synthase induces
endoplasmic reticulum stress in tumor cells. Cancer Res.
67:1262–1269. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zeng L, Wu GZ, Goh KJ, Lee YM, Ng CC, You
AB, Wang J, Jia D, Hao A, Yu Q, et al: Saturated fatty acids
modulate cell response to DNA damage: Implication for their role in
tumorigenesis. PLoS One. 3:e23292008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dengler MA, Weilbacher A, Gutekunst M,
Staiger AM, Vöhringer MC, Horn H, Ott G, Aulitzky WE and van der
Kuip H: Discrepant NOXA (PMAIP1) transcript and NOXA protein
levels: A potential Achilles’ heel in mantle cell lymphoma. Cell
Death Dis. 5:e10132014. View Article : Google Scholar
|
|
9
|
Garcia SB, Barros LT, Turatti A,
Martinello F, Modiano P, Ribeiro-Silva A, Vespúcio MV and Uyemura
SA: The anti-obesity agent Orlistat is associated to increase in
colonic preneoplastic markers in rats treated with a chemical
carcinogen. Cancer Lett. 240:221–224. 2006. View Article : Google Scholar
|
|
10
|
Nairooz S, Ibrahim SH, Sahar MMO and Affan
M: Structural changes of the colonic mucosa induced by Orlistat:
Experimental study. Egypt J Histol. 33:635–648. 2010.
|
|
11
|
Christmann M, Verbeek B, Roos WP and Kaina
B: O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal
tissues and tumors: Enzyme activity, promoter methylation and
immunohistochemistry. Biochim Biophys Acta. 1816:179–190.
2011.PubMed/NCBI
|
|
12
|
Fahrer J and Kaina B:
O6-methylguanine-DNA methyltransferase in the defense
against N-nitroso compounds and colorectal cancer. Carcinogenesis.
34:2435–2442. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nosho K, Kawasaki T, Ohnishi M, Suemoto Y,
Kirkner GJ, Zepf D, Yan L, Longtine JA, Fuchs CS and Ogino S:
PIK3CA mutation in colorectal cancer: Relationship with genetic and
epigenetic alterations. Neoplasia. 10:534–541. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pepponi R, Marra G, Fuggetta MP,
Falcinelli S, Pagani E, Bonmassar E, Jiricny J and D’Atri S: The
effect of O6-alkyl-guanine-DNA alkyltransferase and
mismatch repair activities on the sensitivity of human melanoma
cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and
cisplatin. J Pharmacol Exp Ther. 304:661–668. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Watson AJ and Margison GP:
O(6)-Alkylguanine-DNA alkyl-transferase assay. Methods Mol Med.
28:167–178. 1999.
|
|
16
|
Ranson M, Middleton MR, Bridgewater J, Lee
SM, Dawson M, Jowle D, Halbert G, Waller S, McGrath H, Gumbrell L,
et al: Lomeguatrib, a potent inhibitor of
O6-alkylguanine-DNA-alkyltransferase: Phase I safety,
pharmacodynamic, and pharmacokinetic trial and evaluation in
combination with temozolomide in patients with advanced solid
tumors. Clin Cancer Res. 12:1577–1584. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Srivenugopal KS, Yuan XH, Friedman HS and
Ali-Osman F: Ubiquitination-dependent proteolysis of
O6-methylguanine-DNA methyltransferase in human and
murine tumor cells following inactivation with
O6-benzylguanine or
1,3-bis(2-chloroethyl)-1-nitrosourea. Biochemistry. 35:1328–1334.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Turriziani M, Caporaso P, Bonmassar L,
Buccisano F, Amadori S, Venditti A, Cantonetti M, D’Atri S and
Bonmassar E: O6-(4-bromothenyl)guanine (PaTrin-2), a
novel inhibitor of O6-alkylguanine DNA
alkyl-transferase, increases the inhibitory activity of
temozolomide against human acute leukaemia cells in vitro.
Pharmacol Res. 53:317–323. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pegg AE and Byers TL: Repair of DNA
containing O6-alkyl-guanine. FASEB J. 6:2302–2310.
1992.PubMed/NCBI
|
|
20
|
Kyrtopoulos SA, Anderson LM, Chhabra SK,
Souliotis VL, Pletsa V, Valavanis C and Georgiadis P: DNA adducts
and the mechanism of carcinogenesis and cytotoxicity of methylating
agents of environmental and clinical significance. Cancer Detect
Prev. 21:391–405. 1997.PubMed/NCBI
|
|
21
|
Gouws C and Pretorius PJ:
O6-methylguanine-DNA methyltransferase (MGMT): Can
function explain a suicidal mechanism? Med Hypotheses. 77:857–860.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wojciechowicz K, Cantelli E, Van Gerwen B,
Plug M, Van Der Wal A, Delzenne-Goette E, Song JY, De Vries S,
Dekker M and Te Riele H: Temozolomide increases the number of
mismatch repair-deficient intestinal crypts and accelerates
tumorigenesis in a mouse model of Lynch syndrome. Gastroenterology.
147:1064–1072.e5. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
D’Atri S, Graziani G, Lacal PM, Nisticò V,
Gilberti S, Faraoni I, Watson AJ, Bonmassar E and Margison GP:
Attenuation of O(6)-methylguanine-DNA methyltransferase activity
and mRNA levels by cisplatin and temozolomide in jurkat cells. J
Pharmacol Exp Ther. 294:664–671. 2000.
|
|
24
|
Xiao W and Samson L: In vivo evidence for
endogenous DNA alkylation damage as a source of spontaneous
mutation in eukaryotic cells. Proc Natl Acad Sci USA. 90:2117–2121.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Iyama T and Wilson DM III: DNA repair
mechanisms in dividing and non-dividing cells. DNA Repair (Amst).
12:620–636. 2013. View Article : Google Scholar
|
|
26
|
Ito T, Nakamura T, Maki H and Sekiguchi M:
Roles of transcription and repair in alkylation mutagenesis. Mutat
Res. 314:273–285. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bak ST, Sakellariou D and Pena-Diaz J: The
dual nature of mismatch repair as antimutator and mutator: For
better or for worse. Front Genet. 5:2872014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cohen SA and Leininger A: The genetic
basis of Lynch syndrome and its implications for clinical practice
and risk management. Appl Clin Genet. 7:147–158. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Aquilina G, Biondo R, Dogliotti E, Meuth M
and Bignami M: Expression of the endogenous
O6-methylguanine-DNA-methyltransferase protects Chinese
hamster ovary cells from spontaneous G:C to A:T transitions. Cancer
Res. 52:6471–6475. 1992.PubMed/NCBI
|
|
30
|
Paranjpe A, Zhang R, Ali-Osman F, Bobustuc
GC and Srivenugopal KS: Disulfiram is a direct and potent inhibitor
of human O6-methylguanine-DNA methyltransferase (MGMT)
in brain tumor cells and mouse brain and markedly increases the
alkylating DNA damage. Carcinogenesis. 35:692–702. 2014. View Article : Google Scholar :
|
|
31
|
Xu-Welliver M and Pegg AE: Degradation of
the alkylated form of the DNA repair protein, O(6)-alkylguanine-DNA
alkyltransferase. Carcinogenesis. 23:823–830. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Khan O and Middleton MR: The therapeutic
potential of O6-alkylguanine DNA alkyltransferase
inhibitors. Expert Opin Investig Drugs. 16:1573–1584. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Marchesi F, Turriziani M, Tortorelli G,
Avvisati G, Torino F and De Vecchis L: Triazene compounds:
Mechanism of action and related DNA repair systems. Pharmacol Res.
56:275–287. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bonmassar L, Marchesi F, Pascale E,
Franzese O, Margison GP, Bianchi A, D’Atri S, Bernardini S,
Lattuada D, Bonmassar E, et al: Triazene compounds in the treatment
of acute myeloid leukemia: A short review and a case report. Curr
Med Chem. 20:2389–2401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Seiter K, Katragadda S, Ponce D, Rasul M
and Ahmed N: Temozolomide and cisplatin in relapsed/refractory
acute leukemia. J Hematol Oncol. 2:212009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang J, Stevens MF and Bradshaw TD:
Temozolomide: Mechanisms of action, repair and resistance. Curr Mol
Pharmacol. 5:102–114. 2012. View Article : Google Scholar
|
|
37
|
Niture SK, Velu CS, Smith QR, Bhat GJ and
Srivenugopal KS: Increased expression of the MGMT repair protein
mediated by cysteine prodrugs and chemopreventative natural
products in human lymphocytes and tumor cell lines. Carcinogenesis.
28:378–389. 2007. View Article : Google Scholar
|
|
38
|
Liu L, Allay E, Dumenco LL and Gerson SL:
Rapid repair of O6-methylguanine-DNA adducts protects
transgenic mice from N-methylnitrosourea-induced thymic lymphomas.
Cancer Res. 54:4648–4652. 1994.PubMed/NCBI
|
|
39
|
Nakatsuru Y, Matsukuma S, Nemoto N, Sugano
H, Sekiguchi M and Ishikawa T: O6-methylguanine-DNA
methyltransferase protects against nitrosamine-induced
hepatocarcinogenesis. Proc Natl Acad Sci USA. 90:6468–6472. 1993.
View Article : Google Scholar
|
|
40
|
Griesenbeck JS, Steck MD, Huber JC Jr,
Sharkey JR, Rene AA and Brender JD: Development of estimates of
dietary nitrates, nitrites, and nitrosamines for use with the Short
Willet Food Frequency Questionnaire. Nutr J. 8:162009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Orsolin PC, Silva-Oliveira RG and
Nepomuceno JC: Assessment of the mutagenic, recombinagenic and
carcinogenic potential of orlistat in somatic cells of Drosophila
melanogaster. Food Chem Toxicol. 50:2598–2604. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kridel SJ, Axelrod F, Rozenkrantz N and
Smith JW: Orlistat is a novel inhibitor of fatty acid synthase with
antitumor activity. Cancer Res. 64:2070–2075. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li JN, Gorospe M, Chrest FJ, Kumaravel TS,
Evans MK, Han WF and Pizer ES: Pharmacological inhibition of fatty
acid synthase activity produces both cytostatic and cytotoxic
effects modulated by p53. Cancer Res. 61:1493–1499. 2001.PubMed/NCBI
|
|
44
|
Zecchin KG, Rossato FA, Raposo HF, Melo
DR, Alberici LC, Oliveira HC, Castilho RF, Coletta RD, Vercesi AE
and Graner E: Inhibition of fatty acid synthase in melanoma cells
activates the intrinsic pathway of apoptosis. Lab Invest.
91:232–240. 2011. View Article : Google Scholar
|
|
45
|
Kant S, Kumar A and Singh SM: Tumor growth
retardation and chemosensitizing action of fatty acid synthase
inhibitor orlistat on T cell lymphoma: Implication of reconstituted
tumor microenvironment and multidrug resistance phenotype. Biochim
Biophys Acta. 1840:294–302. 2014. View Article : Google Scholar
|
|
46
|
Bocangel D, Sengupta S, Mitra S and Bhakat
KK: p53-mediated downregulation of the human DNA repair gene
O6-methyl-guanine-DNA methyltransferase (MGMT) via
interaction with Sp1 transcription factor. Anticancer Res.
29:3741–3750. 2009.PubMed/NCBI
|
